Geneva, Switzerland and Boston, MA – January 23, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback